First Time Loading...
T

Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 5 870 ILS 0.95% Market Closed
Updated: May 10, 2024
Section:
 

Relative Value

The Relative Value of one TEVA stock under the Base Case scenario is 10 619.66 ILS. Compared to the current market price of 5 870 ILS, Teva Pharmaceutical Industries Ltd is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TEVA Relative Value
Base Case
10 619.66 ILS
Undervaluation 45%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
0
vs Industry
68
Median 3Y
0.7
Median 5Y
0.7
Industry
2.5
Forward
1.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5
Median 5Y
-4.4
Industry
23.4
Forward
650.8
More Details
13
P/OCF
P/OCF
Price to OCF
13
vs History
33
vs Industry
31
Median 3Y
9.5
Median 5Y
10.2
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
17
Median 3Y
-7.7
Median 5Y
-7.4
Industry
23.6
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
0
vs Industry
35
Median 3Y
1.2
Median 5Y
1.1
Industry
2.1
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
14
vs Industry
52
Median 3Y
1.8
Median 5Y
1.9
Industry
2.6
Forward
2
More Details
4.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.1
vs History
39
vs Industry
49
Median 3Y
3.7
Median 5Y
3.9
Industry
5.2
More Details
7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7
vs History
36
vs Industry
43
Median 3Y
6.2
Median 5Y
6.6
Industry
13.7
Forward
6.8
More Details
9.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
9.2
vs History
49
vs Industry
40
Median 3Y
8.6
Median 5Y
9.2
Industry
17.2
Forward
7.8
More Details
23.9
EV/OCF
EV/OCF
Enterprise Value to OCF
23.9
vs History
66
vs Industry
20
Median 3Y
24.4
Median 5Y
26.1
Industry
16.2
More Details
38.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38.9
vs History
55
vs Industry
13
Median 3Y
36.6
Median 5Y
45.7
Industry
17.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
0
vs Industry
63
Median 3Y
0.7
Median 5Y
0.7
Industry
2
More Details

Multiples Across Competitors

TEVA Competitors Multiples
Teva Pharmaceutical Industries Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Teva Pharmaceutical Industries Ltd
TASE:TEVA
66.1B ILS 1.1 -31.8 7 9.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
733.3B USD 20.4 119.5 58.5 66.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.6B USD 4.2 9.4 11.5 15.1
US
Merck & Co Inc
NYSE:MRK
329.8B USD 5.4 143 35.6 58.2
UK
AstraZeneca PLC
LSE:AZN
191.2B GBP 5 37.8 174.6 278.5
CH
Roche Holding AG
SIX:ROG
177.2B CHF 3 15.4 8.8 10.4
CH
Novartis AG
SIX:NOVN
177.1B CHF 3.3 11.1 8.5 12.4
US
Pfizer Inc
NYSE:PFE
159.1B USD 2.9 -514.9 12.8 20.3
P/E Multiple
Earnings Growth
IL
T
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Average P/E: 54.3
Negative Multiple: -31.8 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
143
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.8
168%
CH
Roche Holding AG
SIX:ROG
15.4
26%
CH
Novartis AG
SIX:NOVN
11.1
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -514.9
680%

See Also

Summary
TEVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
TEVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TEVA stock valuation using valuation multiples.
Wall Street Estimates
TEVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TEVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.